美替诺龙 | 153-00-4

• 物质功能分类: 原料药 - 激素及调节内分泌功能类药 - 雄激素及同化激素类药
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 美替诺龙
• 中文别名: 甲基异睾酮；17beta-羟基-1-甲基-5alpha-雄甾-1-烯-3-酮
• 英文名称: Metenolone
• 英文别名: methenolone；17β-hydroxy-1-methyl-5α-androst-1-en-3-one；(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-1,10,13-trimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 153-00-4
• 化学式: C₂₀H₃₀O₂
• 分子量: 302.457
• InChiKey: ANJQEDFWRSLVBR-VHUDCFPWSA-N

物化性质

• 熔点：
  149.5-152°; mp 160-161° (Popper)
• 比旋光度：
  D +58.9°
• 沸点：
  430.4±45.0 °C(Predicted)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• WGK Germany：
  3
• RTECS号：
  VC2830000
• 海关编码：
  2937290019
• 包装等级：
  III
• 危险类别：
  8
• 危险品运输编号：
  UN 3261 8/PG 2

反应信息

• 作为反应物：
  描述：

  美替诺龙 在 咪唑 、 chromium(VI) oxide 、 4-二甲氨基吡啶 、 氢氧化钾 、 硫酸 、 二苯基二硒醚 、 溶剂黄146 、 亚碘酰苯 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 为溶剂， 反应 115.25h， 生成 1,4-dimethylandrosta-1,4-dien-3,17-dione
  参考文献：
  名称：

  雄烷系列中环多甲基化甾体的区域选择性合成

  摘要：

  普通前体17β-羟基-1-甲基-5α-雄酮-1-en-3-one（13）的适当保护的衍生物14和20已以区域选择性方式转化为高度甲基化的雄甾烯1,4-二烯- 3,17-二酮衍生物6-8。通过衍生自20的动力学二烯酸锂进行甲基化，可以进入1,4-二甲基化衍生物的歧管，而通过热力学二烯酸或等效物对14进行硫代甲基化，然后由阮内镍促进脱硫，从而得到28。这些烷基化方法的组合成功产生了三甲基化的雄烷烃衍生物34。苯亚硒酸酐（BSA）所介导的中间体脱氢23，28，和34然后提供的1,4-二烯烃24，29，和35短靶分子，两个常规步骤6-8。还描述了通过使13受到BSA促进的氧化而容易地合成有效的芳香酶抑制剂5的方法。

  DOI：

  10.1016/s0040-4020(01)89518-1
• 作为产物：
  描述：

  美替诺龙庚酸酯 在 Cunninghamella blakesleeana 作用下， 以 甲醇 为溶剂， 反应 288.0h， 生成 美替诺龙
  参考文献：
  名称：

  Aspergillus niger-mediated biotransformation of methenolone enanthate, and immunomodulatory activity of its transformed products

  摘要：

  Two fungal cultures Aspergillus niger and Cunninghamella blakesleeana were used for the biotransformation of methenolone enanthate (1). Biotransformation with A. niger led to the synthesis of three new (2-4), and three known (5-7) metabolites, while fermentation with C. blakesleeana yielded metabolite 6. Substrate 1 and the resulting metabolites were evaluated for their immunomodulatory activities. Substrate 1 was found to be inactive, while metabolites 2 and 3 showed a potent inhibition of ROS generation by whole blood (IC50= 8.60 and 7.05 mu g/mL), as well as from isolated polymorphonuclear leukocytes (PMNs) (IC50= 14.0 and 4.70 mu g/mL), respectively. Moreover, compound 3 (34.21%) moderately inhibited the production of TNF-alpha, whereas 2 (88.63%) showed a potent inhibition of TNF-alpha produced by the THP-1 cells. These activities indicated immunomodulatory potential of compounds 2 and 3. All products were found to be non-toxic to 3T3 mouse fibroblast cells. (C) 2016 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2016.04.007

文献信息

• MORPHOLINOPURINE DERIVATIVES
  申请人：Nakayama Kiyoshi

  公开号：US20100130492A1

  公开（公告）日：2010-05-27

  There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , R a , R b , R c , and X each have the same meaning as defined in the specification.

  提供了一种新型化合物，它抑制磷脂酰肌醇3-激酶（PI3K）和/或哺乳动物雷帕霉素靶蛋白（mTOR），并表现出抗肿瘤活性。本发明提供了一种由以下式（1）表示的化合物，具有各种取代基，可抑制PI3K和/或mTOR，并表现出抗肿瘤活性： 其中R1、R2、R3、R4、Ra、Rb、Rc和X的含义与规范中定义的含义相同。
• COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF
  申请人：PELOTON THERAPEUTICS, INC.

  公开号：US20180140569A1

  公开（公告）日：2018-05-24

  The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.

  本发明提供了治疗增殖性疾病的方法和药物组合物。该方法涉及向所述受试者施用HIF-2alpha抑制剂和免疫治疗药物的步骤。
• 6-Membered heterocyclic compound and use thereof
  申请人：Shoda Motoshi

  公开号：US20070060590A1

  公开（公告）日：2007-03-15

  A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH 2 and the like; R O1 to R O4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents —CH(OH)— group and the like; and W represent —U 1 —(R W1 )(R W2 )—U 2 —U 3 group (U 1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; R W1 and R W2 represent hydrogen atom and the like; U 2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U 3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoma, ulcerative colitis and the like.

  由通用公式(I)表示的化合物或其盐： [T代表氧原子等；V代表CH2等；RO1至RO4代表氢原子等；A代表具有2至8个碳原子的线型亚烷基或线型亚烯基等；D代表羧基等；X代表亚乙基、亚丙基等；E代表—CH(OH)—基团等；W代表—U1—(RW1)(RW2)—U2—U3基团（U1代表单键、具有1至4个碳原子的亚烷基等；RW1和RW2代表氢原子等；U2代表单键、具有1至4个碳原子的亚烷基等；U3代表具有1至8个碳原子的烷基等），或碳环或杂环化合物的残基]，其可作为预防性和/或治疗性药物的有效成分，用于治疗骨骼疾病如骨质疏松症和骨折、青光眼、溃疡性结肠炎等。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• [EN] BENZIMIDAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEURS UTILISATIONS
  申请人：PELOTON THERAPEUTICS INC

  公开号：WO2015175845A1

  公开（公告）日：2015-11-19

  Benzimidazole derivatives of Formula I, that modulate the activity of ACSS2 are disclosed for therapeutic use. The fused imidazole ring of the compounds disclosed has a diarylmethyl or diarylmethanol moiety attached at the 2-position and the compounds have at least one other substituent at the 5 or 6 position of the benzimidazole. Also disclosed are methods of using the benzimidazole compounds for the treatment of diseases or disorders, such as cancer.

  公开了公式I的苯并咪唑衍生物，其调节ACSS2的活性，用于治疗。所公开的化合物的融合咪唑环在2位上连接有二芳基甲基或二芳基甲醇基团，并且这些化合物在苯并咪唑的5位或6位至少有另一个取代基。还公开了使用苯并咪唑化合物治疗疾病或疾病的方法，如癌症。